Retest Dates vs. Expiry Dates for Herbal Raw Materials: What Your Stability Protocol Should Actually Include

Most quality managers at supplement brands encounter this situation at least once: a 200-lb drum of ashwagandha root extract is sitting in the warehouse, CoA stamped “Retest Date: June 2026” — and it’s already August. The supplier says it’s probably fine. The production team needs to run a batch. And the QA lead is staring at a protocol binder that says nothing about what to actually test.

This is the retest date problem. And it’s far more common in Midwest supplement manufacturing than anyone talks about.

The confusion usually starts with a terminology issue. Retest dates and expiry dates look identical on a CoA — they’re both just dates. But they carry different obligations, different risks, and meaningfully different regulatory implications under 21 CFR Part 111. Getting this distinction right is the difference between a defensible quality decision and a batch rejection waiting to happen.

Retest Dates and Expiry Dates Are Not the Same Thing

An expiry date — sometimes called an expiration date or use-by date — means the material has been shown through stability data to degrade beyond specification limits at that point. You don’t use it past that date, full stop. Most finished supplement products carry expiry dates because the finished dose form has been tested under accelerated and real-time conditions.

A retest date works differently. It means: “We’ve confirmed this material meets specification up to this point. Beyond it, you need to retest before use.” The material isn’t necessarily degraded — it just hasn’t been re-confirmed. If it passes a full retest panel, it’s still usable. If it fails, now you know before it goes into a batch.

Most herbal raw material suppliers assign retest dates rather than expiry dates, typically set at 24 to 36 months from the manufacturing date. The logic is defensible: botanical powders and extracts are complex matrices. Degradation rates depend heavily on packaging type, storage temperature, humidity, and light exposure — all of which vary between customers. A retest date acknowledges that variability honestly, rather than pretending the material exists in a controlled vacuum from mill to production floor.

The regulatory picture matters here. FDA’s 21 CFR 111.83 requires dietary supplement manufacturers to place expiration dating on finished products and support it with testing data. That obligation flows backward through your supply chain. If your finished product expires in 24 months, your raw materials need to be confirmed stable across the full manufacturing-plus-shelf-life window. A supplier’s retest date doesn’t satisfy your own compliance obligation — it’s a data point, not a certificate.

What ICH Q1A(R2) Actually Requires — and Why It Applies to Botanicals

ICH Q1A(R2) is the foundational guideline for stability testing of drug substances and products. Technically it’s pharmaceutical in scope, but the supplement industry — particularly manufacturers with GMP certifications and those supplying international markets — has widely adopted it as the reference framework for stability study design. It’s the language FDA auditors speak.

The core protocol structure from ICH Q1A(R2) is this: long-term testing at 25°C ± 2°C / 60% RH ± 5% RH, evaluated at 0, 3, 6, 9, 12, 18, and 24 months; accelerated testing at 40°C ± 2°C / 75% RH ± 5% RH evaluated at 0, 3, and 6 months. If the accelerated data shows significant degradation at the 6-month pull, you can’t extrapolate a 24-month shelf life claim — you’d need intermediate condition data at 30°C / 65% RH to support anything beyond 12 months.

For botanical raw materials specifically, the accelerated protocol matters because it reveals moisture-driven degradation fast. A hygroscopic turmeric extract can absorb enough water at 75% RH to push its total aerobic microbial count (TAMC) above the USP <61> limit of 10⁴ cfu/g in under 90 days. That failure shows up clearly in an accelerated stability chamber — it would be completely invisible on a warehouse shelf until release testing, which usually doesn’t include microbiology on retained raw material drums.

The practical takeaway: if your supplier doesn’t have a formal stability study on file for the lot you purchased, you’re working from assumption, not data. Requesting that documentation — or commissioning a study through an analytical testing laboratory — is both a quality decision and a meaningful liability mitigation move.

The Retest Panel: Which Tests Actually Matter

Not every CoA test needs to be repeated at a retest. Some assays are stability-sensitive; others are one-time identity checks that don’t change over time. Understanding which is which saves cost and gets you a disposition decision faster.

Here’s what a defensible retest panel for an herbal botanical powder should include:

Botanical identity. Yes, include it — not because the plant species changes in storage, but because contamination or mislabeling errors surface at retesting when a different analytical testing laboratory runs the panel than the original supplier did. HPTLC remains the most widely accepted method for botanical identity under USP standards. DNA barcoding adds confirmation for difficult-to-authenticate species like ginkgo biloba or valerian root.

Potency markers. This is the most stability-sensitive test for most standardized extracts. Ashwagandha standardized to 5% withanolides, black cohosh standardized to 2.5% triterpene glycosides, green tea standardized to 50% EGCG — these marker compounds degrade at measurable rates. HPLC with UV detection is standard. A marker compound drop of more than 10–15% from the original CoA value is a quality flag worth escalating, even if the lot technically stays within specification.

Microbiology: USP <61> and <62>. Botanical powders are agricultural products with inherent microbial loads. Storage in conditions with humidity creep — which happens in many Chicago-area warehouses during July and August — creates conditions for yeast and mold proliferation that wasn’t present at receiving. The USP <62> specified organism list includes Salmonella spp., Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa. These aren’t theoretical risks; they’re documented failure modes in herbal materials stored in sub-optimal conditions.

Moisture content. Loss on drying (LOD) per USP <731>, or Karl Fischer titration for moisture-sensitive materials. Most botanical powders are specified at ≤10% LOD; enzyme-containing blends and probiotic-spiked powders often run ≤5%. A moisture increase at retesting is frequently the leading indicator of other failures — elevated microbial counts, reduced potency, physical caking that affects dose uniformity.

Heavy metals via ICP-MS (USP <232>/<233>). This one surprises people. Heavy metals don’t degrade — they don’t increase with time on their own. But packaging material migration is a documented phenomenon, particularly with HDPE drums stored in humid conditions or near heat sources over extended periods. The USP <232> oral elemental impurity limits — 1.5 µg/g for arsenic, 5.0 µg/g for lead, 1.5 µg/g for mercury, 0.5 µg/g for cadmium — are the benchmarks. If your original CoA showed arsenic at 1.2 µg/g, running ICP-MS at the 30-month retest is warranted, not optional.

Designing a Protocol When No USP Monograph Exists

This is where brands get stuck. Common botanicals like turmeric rhizome, ginger root, and black pepper extract have USP monographs with defined test methods and specification limits. But many ingredients in today’s supplement supply chain don’t: lion’s mane mushroom extract, sea buckthorn berry powder, tart cherry concentrate, fermented black garlic. No monograph means no reference test panel, no established limits, and no built-in stability guidance.

The practical approach is to build a specification from the supplier’s CoA and your own internal data, then design the stability protocol around it. Define the critical quality attributes (CQAs) for that specific material: which marker compounds drive efficacy? What microbial limits are consistent with the ingredient’s intended use and finished product category? What’s the acceptable moisture range based on the extraction process and primary packaging?

Once those CQAs are defined, the stability study is straightforward: store samples under ICH Q1A conditions, pull at defined timepoints, run the CQA panel at each pull. Six months of accelerated data gives you enough information to assign a preliminary retest date while long-term data accumulates at 25°C. It’s not glamorous science — but it’s the documentation that makes an FDA audit survivable.

For Midwest brands receiving raw materials through our Chicago sample intake facility, the most practical first step is commissioning a T=0 baseline panel on current inventory. That baseline is what every subsequent retest gets measured against — and it’s the documentation your QA team needs to demonstrate due diligence when an auditor asks how you determined your ingredient was still suitable for use.

What FDA Expects to See During an Inspection

FDA’s Office of Dietary Supplement Programs (ODSP) has been explicit about ingredient identity and retesting expectations in recent Warning Letters. The recurring theme across those letters: brands can’t simply accept supplier CoAs as sole identity verification, and they can’t use ingredients beyond established retest dates without documented justification.

The documentation standard is clear. You need: the original CoA with the supplier’s retest date, your internal SOP for what triggers a retest and what the test panel includes, laboratory records from the retest performed by a qualified analytical testing laboratory, and a written disposition decision with a QA signature and date. Absent any one of those four elements, the batch is exposed during an inspection.

One detail that consistently trips up smaller brands: the retest must be run by a laboratory qualified to perform the specific test methods. Not an in-house team using a color-change kit. HPTLC or DNA barcoding for botanical identity, validated HPLC for potency, plate-based microbiology per USP <61>/<62>, and ICP-MS for elemental impurities all require instrumentation and analyst training that most manufacturing facilities don’t maintain in-house. That’s exactly why a contract laboratory arrangement — with a single CoA covering the full panel — makes more practical sense than managing three or four separate vendor relationships on a rolling retest schedule.

Before the Retest Date, Not After

If a retest date on one of your raw materials is approaching within 60 days, act now. Commission the retest panel early enough that you have time to make a batch decision before you’re stalling a production run. If the material fails a critical attribute, a 60-day buffer gives you time to source a replacement without disrupting manufacturing schedules. If it passes, you have current third-party data supporting continued use and a documented quality decision that stands up to scrutiny.

Build the retest schedule into your raw material tracking system. Flag CoAs at receiving, calculate the retest date automatically, and set a 60-day alert. And if your current analytical testing laboratory can’t run HPTLC, validated HPLC potency, USP microbiology, and ICP-MS from a single sample submission — you’re managing more vendor complexity than the problem requires.

Stability isn’t complicated quality work. But it’s exactly the kind of documentation that keeps a GMP inspection from turning into a Warning Letter.

---

Written by Nour Abochama, VP Operations, Qalitex | Quality Consultant, Ayah Labs. Learn more about our team

Ship your sample to our Chicago facility — get a Qalitex CoA in 5–7 days Contact us

Related from our network

• ISO 17025-accredited herbal supplement testing for brands across North America — Qalitex Laboratories performs HPTLC botanical identity, ICP-MS heavy metals (USP <232>/<233>), validated HPLC potency, and USP microbiology from a single sample submission with a fully accredited CoA.